Mark Merchant - Associate Director and Senior Scientist (Technology), Translational Oncology

Mark Merchant

Associate Director and Senior Scientist (Technology), Translational Oncology

"Genentech is a terrific place to do science. There is a terrific blend of cutting-edge basic research and innovate translational science all aimed at one thing – improving the lives of patients. It’s a terrifically rewarding environment to work in, both professionally and personally."
17
Years at Genentech
47
Publications
2
Awards & Honors

I received my Ph.D. in Richard Longnecker’s lab studying Epstein Barr viral proteins that signal to maintain viral latency, contributing to oncogenesis (Northwestern University – 2001). Following my graduate work I joined the lab of Frederic de Sauvage at Genentech as a post-doctoral fellow where I studied components of the Hedgehog pathway and how they mediate oncogenic signaling. In 2005 I joined the Department of Translational Oncology as a Scientist and have since worked on developing numerous small and large molecule cancer therapeutics.

At Genentech we strive to bring innovative and life-saving therapies to patients who urgently need them. With this focus we take on some of the most challenging problems in a highly collaborative and effective way. I feel honored to work side-by-side with some of the smartest, most creative and dedicated scientists rising to this challenge every day.

Featured Publication

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.

PLoS One. 2017 Oct 5;12(10):e0185862.

Merchant M, Moffat J, Schaefer G, Chan J, Wang X, Orr C, Cheng J, Hunsaker T, Shao L, Wang SJ, Wagle MC, Lin E, Haverty PM, Shahidi-Latham S, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Huang SA, Schwarz J, Belvin M, Kirouac D, Junttila MR.